Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2017 3
2018 8
2019 5
2020 9
2021 11
2022 6
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors.
Ghosh AK, Yadav M, Iddum S, Ghazi S, Lendy EK, Jayashankar U, Beechboard SN, Takamatsu Y, Hattori SI, Aamano M, Higashi-Kuwata N, Mitsuya H, Mesecar AD. Ghosh AK, et al. Among authors: hattori si. Eur J Med Chem. 2024 Mar 5;267:116132. doi: 10.1016/j.ejmech.2024.116132. Epub 2024 Feb 1. Eur J Med Chem. 2024. PMID: 38335815
Correction for Nakajima et al., "Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations".
Nakajima S, Watashi K, Kato T, Muramatsu M, Wakita T, Tamura N, Hattori S-i, Maeda K, Mitsuya H, Yasutake Y, Toyoda T. Nakajima S, et al. Among authors: hattori s i. J Virol. 2024 Mar 19;98(3):e0182323. doi: 10.1128/jvi.01823-23. Epub 2024 Feb 2. J Virol. 2024. PMID: 38305151 Free PMC article. No abstract available.
Exploratory Studies of Effective Inhibitors against the SARS-CoV-2 Main Protease by Halogen Incorporation and Amide Bond Replacement.
Tsuji K, Kobayakawa T, Ishii T, Higashi-Kuwata N, Azuma C, Shinohara K, Miura Y, Yamamoto K, Nishimura S, Hattori SI, Bulut H, Mitsuya H, Tamamura H. Tsuji K, et al. Among authors: hattori si. Chem Pharm Bull (Tokyo). 2023;71(12):879-886. doi: 10.1248/cpb.c23-00562. Chem Pharm Bull (Tokyo). 2023. PMID: 38044140 Free article.
GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants.
Aoki M, Aoki-Ogata H, Bulut H, Hayashi H, Takamune N, Kishimoto N, Tanaka H, Higashi-Kuwata N, Hattori SI, Das D, Venkateswara Rao K, Iwama K, Davis DA, Hasegawa K, Murayama K, Yarchoan R, Ghosh AK, Pau AK, Machida S, Misumi S, Mitsuya H. Aoki M, et al. Among authors: hattori si. Sci Adv. 2023 Jul 14;9(28):eadg2955. doi: 10.1126/sciadv.adg2955. Epub 2023 Jul 12. Sci Adv. 2023. PMID: 37436982 Free PMC article.
Exploration of imatinib and nilotinib-derived templates as the P2-Ligand for HIV-1 protease inhibitors: Design, synthesis, protein X-ray structural studies, and biological evaluation.
Ghosh AK, Mishevich JL, Kovela S, Shaktah R, Ghosh AK, Johnson M, Wang YF, Wong-Sam A, Agniswamy J, Amano M, Takamatsu Y, Hattori SI, Weber IT, Mitsuya H. Ghosh AK, et al. Among authors: hattori si. Eur J Med Chem. 2023 Jul 5;255:115385. doi: 10.1016/j.ejmech.2023.115385. Epub 2023 Apr 21. Eur J Med Chem. 2023. PMID: 37150084 Free PMC article.
Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2.
Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, Takamune N, Kishimoto N, Hattori SI, Das D, Uemura Y, Shimizu Y, Aoki M, Hasegawa K, Suzuki S, Nishiyama A, Saruwatari J, Shimizu Y, Sukenaga Y, Takamatsu Y, Tsuchiya K, Maeda K, Yoshimura K, Iida S, Ozono S, Suzuki T, Okamura T, Misumi S, Kawaoka Y, Tamamura H, Mitsuya H. Higashi-Kuwata N, et al. Among authors: hattori si. Nat Commun. 2023 Feb 25;14(1):1076. doi: 10.1038/s41467-023-36729-0. Nat Commun. 2023. PMID: 36841831 Free PMC article.
Potent and biostable inhibitors of the main protease of SARS-CoV-2.
Tsuji K, Ishii T, Kobayakawa T, Higashi-Kuwata N, Azuma C, Nakayama M, Onishi T, Nakano H, Wada N, Hori M, Shinohara K, Miura Y, Kawada T, Hayashi H, Hattori SI, Bulut H, Das D, Takamune N, Kishimoto N, Saruwatari J, Okamura T, Nakano K, Misumi S, Mitsuya H, Tamamura H. Tsuji K, et al. Among authors: hattori si. iScience. 2022 Nov 18;25(11):105365. doi: 10.1016/j.isci.2022.105365. Epub 2022 Nov 1. iScience. 2022. PMID: 36338434 Free PMC article.
Generation of Angiotensin-Converting Enzyme 2/Transmembrane Protease Serine 2-Double-Positive Human Induced Pluripotent Stem Cell-Derived Spheroids for Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Drug Evaluation.
Higashi-Kuwata N, Yabe SG, Fukuda S, Nishida J, Tamura-Nakano M, Hattori SI, Okochi H, Mitsuya H. Higashi-Kuwata N, et al. Among authors: hattori si. Microbiol Spectr. 2022 Dec 21;10(6):e0349022. doi: 10.1128/spectrum.03490-22. Epub 2022 Oct 31. Microbiol Spectr. 2022. PMID: 36314907 Free PMC article.
48 results